Psychopharmacological treatment in the RAISE-ETP study: Outcomes of a manual and computer decision support system based intervention

American Journal of Psychiatry

Volumn 175, Issue 2, 2018, Pages 169-179

  Robinson, Delbert G ^a   Schooler, Nina R ^b   Correll, Christoph U ^c   John, Majnu ^d   Kurian, Benji T ^e   Marcy, Patricia ^e   Miller, Alexander L ^a   Pipes, Ronny ^f   Trivedi, Madhukar H ^g   Kane, John M ^h  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^c ZUCKER HILLSIDE HOSPITAL   (United States)

^d Downstate Health Sciences University   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^f HOFSTRA UNIVERSITY   (United States)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^h University of Texas Health Science Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; ANTIDEPRESSANT AGENT; CHOLESTEROL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PSYCHOTROPIC AGENT; TRIACYLGLYCEROL;

ADULT; AMENORRHEA; BLOOD SAMPLING; BLURRED VISION; BODY WEIGHT GAIN; BODY WEIGHT LOSS; BREAST DISCHARGE; BREAST DISEASE; COMMUNITY CARE; CONFERENCE PAPER; CONSTIPATION; CONTROLLED STUDY; DECISION SUPPORT SYSTEM; DIET RESTRICTION; DIZZINESS; DROWSINESS; FATIGUE; FEMALE; HUMAN; HYPERSALIVATION; INCREASED APPETITE; INSOMNIA; LABORATORY TEST; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; NAUSEA; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; RESTLESSNESS; RIGIDITY; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; VITAL SIGN; XEROSTOMIA; ADOLESCENT; BLOOD; BLOOD PRESSURE; BODY MASS; CLINICAL DECISION SUPPORT SYSTEM; COMPARATIVE STUDY; DEPRESSION; EARLY INTERVENTION; GLUCOSE BLOOD LEVEL; INSULIN RESISTANCE; MENTAL HEALTH RECOVERY; MENTAL HEALTH SERVICE; METABOLISM; OBESITY; ODDS RATIO; PRACTICE GUIDELINE; PROCEDURES; PROTOCOL COMPLIANCE; PSYCHOLOGY; PSYCHOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; WAIST CIRCUMFERENCE; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COMMUNITY MENTAL HEALTH SERVICES; DECISION SUPPORT SYSTEMS, CLINICAL; DEPRESSION; EARLY MEDICAL INTERVENTION; FEMALE; GLYCATED HEMOGLOBIN A; GUIDELINE ADHERENCE; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; MENTAL HEALTH RECOVERY; ODDS RATIO; OVERWEIGHT; PRACTICE GUIDELINES AS TOPIC; PSYCHOTIC DISORDERS; PSYCHOTROPIC DRUGS; QUALITY OF LIFE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TRIGLYCERIDES; WAIST CIRCUMFERENCE; YOUNG ADULT;

EID: 85041674783     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2017.16080919     Document Type: Conference Paper

References (33)

1. Bertolote J, McGorry P: Early intervention and recovery for young people with early psychosis: consensus statement. Br J Psychiatry Suppl 2005;48:s116-s119
2. Craig T K J, Garety P, Power P, et al: The Lambeth Early Onset (LEO) team: randomised controlled trial of the effectiveness of specialised care for early psychosis. BMJ 2004;329:1067
3. Grawe RW, Falloon I R H, Widen JH, et al: Two years of continued early treatment for recent-onset schizophrenia: a randomised controlled study. Acta Psychiatr Scand 2006;114:328-336
4. Jørgensen P, Nordentoft M, Abel MB, et al: Early detection and assertive community treatment of young psychotics: the OPUSstudy rationale and design of the trial. Soc Psychiatry Psychiatr Epidemiol 2000;35:283-287
5. Kane JM, Robinson DG, Schooler NR, et al: Comprehensive versus usual community care for first-episode psychosis: 2-year outcomes from the NIMH RAISE Early Treatment Program. Am J Psychiatry 2016;173:362-372
6. Kuipers E, Holloway F, Rabe-Hesketh S, et al: An RCT of early intervention in psychosis: Croydon Outreach and Assertive Support Team (COAST). Soc Psychiatry Psychiatr Epidemiol 2004;39:358-363
7. Ruggeri M, Bonetto C, Lasalvia A, et al: Feasibility and effectiveness of a multi-element psychosocial intervention for first-episode psychosis: results from the cluster-randomized controlled GET UP PIANO trial in a catchment area of 10 million inhabitants. Schizophr Bull 2015;41:1192-1203
8. Srihari VH, Tek C, Kucukgoncu S, et al: First-episode services for psychotic disorders in the US public sector: a pragmatic randomized controlled trial. Psychiatr Serv 2015;66:705-712
9. Kane JM, Schooler NR, Marcy P, et al: The RAISE Early Treatment Program for first-episode psychosis: background, rationale, and study design. J Clin Psychiatry 2015;76:240-246
10. Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276
11. Addington D, Addington J, Schissel B: A depression rating scale for schizophrenics. Schizophr Res 1990;3:247-251
12. Mueser KT, Penn DL, Addington J, et al: The NAVIGATE program for first-episode psychosis: rationale, overview, and description of psychosocial components. Psychiatr Serv 2015;66:680-690
13. Barnes TR; Schizophrenia Consensus Group of British Association for Psychopharmacology: Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2011;25:567-620
14. Buchanan RW, Kreyenbuhl J, Kelly DL, et al: The 2009 schizophrenia PORTpsychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010;36:71-93
15. Canadian Psychiatric Association: Clinical practice guidelines: treatment of schizophrenia. Can J Psychiatry 2005;50(suppl 1):7S-57S
16. Hasan A, Falkai P, Wobrock T, et al: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry 2013;14:2-44
17. Moore TA, Buchanan RW, Buckley PF, et al: The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry 2007;68:1751-1762
18. Adams JR, Drake RE: Shared decision-making and evidence-based practice. Community Ment Health J 2006;42:87-105
19. Green AI, Lieberman JA, Hamer RM, et al: Olanzapine and haloperidol in first episode psychosis: two-year data. Schizophr Res 2006;86:234-243
20. Schooler N, Rabinowitz J, Davidson M, et al: Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry 2005;162:947-953
21. Koreen AR, Siris SG, Chakos M, et al: Depression in first-episode schizophrenia. Am J Psychiatry 1993;150:1643-1648
22. NAVIGATE Psychopharmacological Treatment Manual. https://raiseetp.org/studymanuals/Psychopharmacology%20Manual.pdf
23. Rosenheck RA, Leslie DL, Sindelar J, et al: Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry 2006;163:2080-2089
24. McHorney CA: The Adherence Estimator: a brief, proximal screener for patient propensity to adhere to prescription medications for chronic disease. Curr Med Res Opin 2009;25:215-238
25. McHorney CA, Victor Spain C, Alexander CM, et al: Validity of the adherence estimator in the prediction of 9-month persistence with medications prescribed for chronic diseases: a prospective analysis of data from pharmacy claims. Clin Ther 2009;31:2584-2607
26. RAISEETP Statistical Analysis Plan. http://raiseetp.org/studymanuals/RAISE-Statistical-Plan. pdf
27. Benjamini Y, Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Methodol 1995;57:289-300
28. Glickman ME, Rao SR, Schultz MR: False discovery rate control is a recommended alternative to Bonferroni-type adjustments in health studies. J Clin Epidemiol 2014;67:850-857
29. Robinson DG, Schooler NR, John M, et al: Prescription practices in the treatment of first-episode schizophrenia spectrum disorders: data from the national RAISE-ETP study. Am J Psychiatry 2015;172:237-248
30. Helfer B, Samara MT, Huhn M, et al: Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis. Am J Psychiatry 2016;173:876-886
31. Garety PA, Craig T K J, Dunn G, et al: Specialised care for early psychosis: symptoms, social functioning, and patient satisfaction: randomised controlled trial. Br J Psychiatry 2006;188:37-45
32. Petersen L, Jeppesen P, Thorup A, et al: A randomised multicentre trial of integrated versus standard treatment for patients with a first episode of psychotic illness. BMJ 2005;331:602
33. Kreyenbuhl JA, Medoff DR, McEvoy JP, et al: The RAISE Connection Program: psychopharmacological treatment of people with a first episode of schizophrenia. Am Psychiatr Serv 2016;67:1300-1306